Hmpl 523 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Hmpl 523. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Hmpl 523 Today - Breaking & Trending Today
Hutchmed (China) Ltd.’s sovleplenib (HMPL-523) met the primary endpoint of durable response rate and all secondary endpoints in the pivotal phase III trial in adults with primary immune thrombocytopenia (ITP) in China. ....